Measurement of NAD+ Synthesis in Human Skeletal Muscle

Not Applicable

Completed

• Conditions: Skeletal Muscle

• Registration Number: NCT04905446
• Lead Sponsor: AdventHealth Translational Research Institute

Brief Summary

The key objective of this pilot research study is to dose human volunteers with a heavy (non-radioactive) isotope derivative of nicotinamide to detect NAD synthesis in human skeletal muscle. The ultimate goal is to examine the impact of lifestyle choices, aging, nutraceuticals, and drugs on the rate of NAD synthesis in human subjects.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-05-21
• Study First Submitted QC: 2021-05-21
• Study First Posted: 2021-05-27
• Study Start: 2021-09-10
• Primary Completion: 2022-06-14
• Study Completion: 2024-12-20
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-12
• Last Update Posted: 2025-03-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 15

Inclusion Criteria

1. Healthy male subjects who, at the time of screening are between the ages of 21 to 40 years of age, inclusive.
2. BMI between 20-30 kg/m2 at the screening visit (SV)
3. Understands the procedures and agrees to participate by giving written informed consent
4. Willing and able to comply with the scheduled study day and other study procedures

Exclusion Criteria

Acute or chronic medical conditions or medication that would contraindicate the participation in the research testing or could potentially affect metabolic function including, but not limited to:

1. History of type 1 or type 2 diabetes mellitus, including pre-diabetes (HbA1c > 5.7)
2. History of any antihyperglycemic agent (e.g., insulin)
3. Currently taking medications that can alter glucose homeostasis (e.g., steroids, glucocorticoids, nicotinic acid) or skeletal muscle metabolism
4. History of taking Tru Niagen, Basis (or any other NR-containing NAD+ booster) or niacin supplements.
5. Any bleeding disorders
6. Currently taking any aspirin (ASA) (including baby ASA) or NSAIDs (ibuprofen, naproxen, etc.) that cannot be safely stopped throughout the study. There is a recommended hold on NSAIDs and/or ASA for at least 2 days prior to biopsy, although not exclusionary
7. Presence of bruising in lower extremities
8. Any major surgery within the past 3 months
9. Any acute or chronic infections
10. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological or allergic diseases, but excluding untreated, asymptomatic, seasonal allergies at the time of intervention.
11. Previous difficulty with lidocaine or other local anesthetic agents
12. Thyroid dysfunction (suppressed TSH, elevated TSH <10 µIU/ml if symptomatic or elevated TSH >10 µIU/ml if asymptomatic)
13. Uncontrolled hypertension (BP >160 mmHg systolic or >100 mmHg diastolic)
14. Use of tobacco or nicotine-containing products within the last 12 months.
15. Chronic kidney disease with GFR of < 60
16. Anemia (hemoglobin <12 g/dl) during screening
17. History of human immunodeficiency virus (HIV), hepatitis B or hepatitis C
18. Liver function testing for ALT or AST greater than or equal to 2 times the upper limit of normal
19. Participation in studies involving investigational drug(s) within 30 days prior to Screening visit
20. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to Screening (participants may not donate blood any time during the study, through the final study day)
21. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete study days Labs may be repeated at the discretion of the PI, MI or Sub-investigators (Sub-I).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Measurement of NAD+ mass isotopomers in extracts from human muscle and skin tissue biopsies as determined by liquid chromatography-mass spectrometry (LC-MS)	4 weeks

Trial Locations

Locations (1)

AdventHealth Translational Research Institute; 🇺🇸 Orlando, Florida, United States